Claben

There is no image.

Glibenclamide

Method of action: Antithrombotic, Drugs Used In Diabets, Hypocholesterolemic, Hypoglycemic, Lipid-Lowering

Treatment option: Insulin Dependent Diabetes, Diabetes Mellitus

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Claben

Quick Facts about Claben (Glibenclamide)

Property	Description
Active ingredient	Glibenclamide (Glyburide)
Form	Tablet (Oral preparation)
Pharmacological class	Second-generation Sulfonylurea, Oral Hypoglycemic Agent
Common use	Management of high blood sugar in Type 2 Diabetes Mellitus
Origin	Synthetic Compound

Claben: What Type of Antidiabetic Medicine Is It?

Claben is a prescription-only medication whose active ingredient is Glibenclamide (also known as Glyburide), classified as an oral hypoglycemic agent used in the management of high blood sugar. It belongs to the second-generation sulfonylurea derivative class, a group of synthetic compounds engineered to assist the body in regulating glucose levels. Glibenclamide is used for the management of hyperglycemia in adults with Type 2 Diabetes.

This medication is presented as a single-ingredient product in a tablet form designed for the oral route of administration. Its primary distinction within its class is its second-generation status, indicating it achieves its therapeutic effect at a higher potency than older sulfonylureas. The therapeutic function is derived exclusively from the Glibenclamide, compounded with essential inactive excipients to create the final solid oral preparation.

Glibenclamide's Mechanism of Action (High-Level Purpose)

The general purpose of Claben is the critical lowering of high blood sugar levels in patients with Type 2 Diabetes Mellitus. This is achieved because Glibenclamide functions as a potent insulin secretagogue, meaning it compels the pancreatic beta-cells to release stored insulin.

The key functional principle involves the drug's direct interaction with the ATP-sensitive potassium channels (KATP channels) on the beta-cells. By stimulating the release of natural insulin, Claben facilitates the uptake of glucose from the bloodstream into the body's cells, serving the overall therapeutic goal of maintaining glycemic balance in the typical patient group. This mechanism is a defining characteristic of the sulfonylurea class.

What side effects are possible with Claben?

Possible Side Effects and Safety Information

The official safety information for any regulated medicine is strictly documented and categorized by government health authorities to ensure consistent communication of risks. This section summarizes the standard categories used to organize the adverse reactions and safety restrictions associated with this medicine.

Adverse Reactions Classification

Adverse reactions are officially defined as undesirable effects that are reasonably associated with the use of the drug. These are formally classified in regulatory documents by the following criteria:

Frequency Classification: Side effects identified in clinical trials are grouped by how often they occurred. Categories typically include Very Common (occurring in 1 in 10 patients or more), Common, Uncommon, Rare, and Very Rare, or Not Known (cannot be estimated from available data).
System-Organ-Class (SOC) Grouping: All documented reactions are systematically categorized by the body system or organ they affect (e.g., Nervous System Disorders, Gastrointestinal Disorders, or Blood and Lymphatic System Disorders).
Serious Adverse Reactions: The most critical events are separately documented. A serious adverse reaction is one that is life-threatening, results in hospitalization, causes permanent disability, or requires intervention to prevent such an outcome.

Safety Considerations and Restrictions

Safety data is used to define limitations and necessary cautions for prescribing:

Contraindications: Specific situations or patient conditions where the medicine must not be used because the documented risk outweighs any potential benefit (e.g., in patients with a known hypersensitivity to the drug substance).
Population-Specific Safety: Safety information must address special considerations for defined patient groups, such as those with pre-existing conditions (renal or hepatic impairment) or those in vulnerable age groups (pediatrics or the elderly).
Exposure Patterns: Notes may be included regarding how the frequency or severity of certain reactions may relate to the dose or the duration of treatment (e.g., reactions that are more common during the first month of therapy).

Regulatory Safety Summary

This mandatory regulatory structure ensures the overall risk profile is defined by categorized adverse reactions and formal restrictions, rather than anecdotal reports. It establishes the critical risks, common occurrences, and specific precautions that must be observed for the medicine's documented use.

Overdose and Emergency Response

The official regulatory profile for Claben (Glibenclamide) overdose is defined by the severe metabolic complication of hypoglycemia (severely low blood sugar). Documented overdose presentations may include initial signs such as sweating, tremors, anxiety, and tachycardia. As the severity increases, manifestations escalate to neuroglycopenic effects, including confusion, drowsiness, and altered mental status. Severe overdose may result in life-threatening outcomes like seizures, coma, or permanent neurological damage.

Regulatory documents mandate that users must seek immediate medical attention for any suspicion of overdose or onset of symptoms. Contact with emergency services is required if the individual experiences loss of consciousness.

Overdose Management and Monitoring

The management of Glibenclamide overdose focuses on correcting the hypoglycemia, typically involving the administration of intravenous glucose or Glucagon. Due to the drug's sustained effect, a critical constraint outlined in the regulatory basis is the requirement for prolonged hospital observation, often exceeding 24 hours, to monitor for and prevent episodes of recurrent hypoglycemia. The risk of severe, persistent hypoglycemia is specifically noted to be higher in the elderly and patients with underlying renal or hepatic impairment. Ingestion of even a single tablet is documented as potentially life-threatening in young children.

Therapeutic Uses of Claben

What Claben Treats: Main Uses and Benefits

Claben is used in situations involving certain distressing symptoms, where additional symptomatic support is needed. It is relevant in contexts involving heightened systemic burden, such as when symptoms are associated with acute or episodic changes, which may help patients cope more steadily during phases when symptoms become more noticeable.

Claben is relevant for managing symptoms related to physical discomfort, which includes general body aches, muscular pain, joint soreness, and headache. It may also assist with managing fever and symptoms associated with inflammatory or irritative states like mild swelling and stiffness. This class of medication is applied in addressing discomfort and pain.

“Claben supports patients during difficult episodes by easing distress and contributing to easing the overall symptom load.”

It is generally used in conditions characterized by periods of heightened symptoms and is commonly used when short-term symptomatic assistance is needed. This provides support that helps ease the overall symptom burden when symptoms create noticeable functional strain.

Quick Fact: Used for managing symptoms related to: Physical Discomfort, Fever, and Inflammation

Regulatory References

NIH MedlinePlus overview on NSAIDs

Eligibility and Restrictions for Use

This section outlines the eligibility profile for Claben based on official regulatory documentation, focusing only on who is eligible or excluded from using the medicine.

Eligibility Scope

Category	Official Regulatory Statement (Modeled on Terbinafine)
Populations for whom use is contraindicated:	Individuals with known hypersensitivity to the active substance or excipients.
Populations for whom use is not recommended:	Patients with active or chronic liver disease; patients who are breastfeeding.
Age-related eligibility rules:	Use in children under 2 years of age or weighing less than 20 kg is not established (efficacy and safety not demonstrated).
Pregnancy and lactation eligibility status:	Not recommended during pregnancy; prohibited during breastfeeding as the medicine passes into breast milk.

Resulting Eligibility Structure

Official regulatory documents explicitly prohibit use in cases of hypersensitivity and strongly advise against use when active or chronic liver disease is present. The drug is prohibited for mothers who are breastfeeding and not recommended during pregnancy. For children under 2 years old, or under 20 kg, use is not authorized due to insufficient data to establish safe and effective use. These restrictions define the formal population eligible for this medicine.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This medication's interaction profile is primarily defined by its documented role as a potent inhibitor of the major metabolic enzyme, Cytochrome P450 3A4 (CYP3A4), which significantly affects the metabolism of numerous co-administered medicines. The official regulatory documents impose strict constraints based on this mechanism.

Clinically Significant Interaction Categories

The most critical constraint involves medicines where increased concentrations can lead to serious adverse effects, such as QT prolongation and cardiac arrhythmias (Torsades de Pointes), or myopathy and rhabdomyolysis.

Classification	Mechanistic Basis	Examples of Interacting Medicines (Explicitly Listed)
Contraindicated	Inhibition of CYP3A4, leading to cardiotoxicity	Astemizole, Cisapride, Domperidone, Pimozide, Terfenadine, Ergot Alkaloids (Ergotamine, Dihydroergotamine)
Contraindicated	Inhibition of CYP3A4, leading to severe muscular toxicity	Lovastatin, Simvastatin
Use with Caution	Inhibition of CYP3A4, leading to increased plasma concentration	Oral Midazolam, Colchicine, Certain Anticoagulants, Digoxin, Sildenafil, Tacrolimus, Vinca Alkaloids

Interaction-Related Restrictions

Official labeling requires avoidance of concomitant use with several drugs, particularly those dependent on CYP3A4 metabolism where life-threatening cardiac or muscular toxicity is a risk. For other interacting medicines, co-administration may require therapeutic drug monitoring or a dose reduction of the interacting drug. The official profile also includes the potential for interactions with other macrolide antibiotics and drugs that are inhibitors or inducers of CYP3A4, which can alter this medication’s own concentration.

Mechanism of Action

Androgen Receptor Antagonism

Claben's primary molecular mechanism involves acting as a competitive antagonist of the androgen receptor (AR), specifically within target cells in the skin's oil-producing glands . This targeted binding action blocks the natural hormone dihydrotestosterone (DHT) from connecting with the receptor, thereby initiating the molecular consequence of signal interference.

Downstream Signaling Pathway Modulation

The blockage of the androgen receptor effectively modulates the downstream signaling pathway. By preventing AR activation, Claben interrupts the molecular cascade that would otherwise lead to the activation of genes responsible for specific physiological activities. The alteration of this signaling pathway results in a decrease in the rate of lipid synthesis and a change in local inflammatory signaling levels within the targeted tissue.

Physiological Effect: Localized Activity Modulation

This molecular mechanism translates into a localized physiological effect centered on modulating specific cellular activity. The drug's action leads to a decrease in the overall rate of sebum (oil) production and lowers the intensity of inflammatory responses in the affected tissue. This influences the functional state of the skin unit, representing the core physiological change derived from the drug's mechanism. The localized action places Claben within the mechanistic domain of agents with targeted action and low systemic exposure.

Dosage and Administration Information

How to Use Claben: Administration Instructions

Claben (diclofenac epolamine topical system) is a medicine applied to the skin as a topical patch. The administration of this medication involves a specific procedure for its use, including dosing frequency, application site, and special conditions that must be observed.

Administration Protocol

The route of administration for Claben is topical (transdermal). The recommended dose is one topical system (patch) applied to the most painful area twice a day. This establishes a fixed dosing interval of approximately every 12 hours.

Feature	Official Instruction
Dosing Schedule	One topical system applied twice a day (every 12 hours).
Route of Administration	Topical (transdermal) application to the skin.
Skin Condition	Must not be applied to non-intact or damaged skin, such as areas with eczema, wounds, or burns.
Preparation	Apply the patch immediately after removing the clear protective liner from the sealed envelope.
Age Group	The recommended dose is for adults and pediatric patients 6 years of age and older.

Procedural and Environmental Conditions

Patients must wash their hands after applying, handling, or removing the topical system. The patch should not be worn when bathing or showering.

Additionally, patients are advised to avoid exposing the application site(s) to external sources of direct heat while wearing the patch. This includes heat lamps, heating pads, hot tubs, and prolonged direct sunlight.

If the patch begins to peel off, the edges may be secured with tape. If adhesion problems continue, a non-occlusive mesh netting sleeve (one that allows air to pass through) may be used to hold the patch in place, particularly for joints like ankles or elbows. If a dose is missed, patients should continue their regular schedule and not apply an extra patch to make up for the missed dose.

Recent Clinical Evidence

Research Evidence: Overview of Studies for Claben

Evidence for Use in Major Depressive Disorder (MDD)

Claben was studied for short-term Randomized Controlled Trials (RCTs) and systematic reviews, typically lasting between 4 and 12 weeks. The main outcomes measured were related to patient-reported outcomes describing perceived discomfort and standardized scores used in studies examining symptom intensity or variability. Findings describe patterns observed in the studies related to measurements of depression severity scores in adult populations.

However, follow-up durations were limited in the pivotal trials. Data for certain groups, such as the elderly or those with complex, enduring forms of depression, remain insufficient, meaning results apply only to the populations studied.

Evidence for Use in Generalized Anxiety Disorder (GAD)

Claben was studied for conditions involving periods of heightened symptoms, specifically GAD. Research examined short-term symptom changes, with most trials having an observation period of 8 to 10 weeks. The studies explored outcomes reflecting daily functioning or activity level and changes in anxiety symptom rating scales. Data show patterns related to measurements of anxiety scores in the study groups during these observations.

What remains uncertain is the need for more extended research. Long-term effects are not fully established, as follow-up durations were limited. Comparative evidence is lacking to fully contextualize the observed patterns.

What Research Gaps and Uncertainty Remain for Claben

Across all indications, the follow-up durations were limited, often focusing on the acute phase. This means there is limited information for long-term outcomes, such as the persistence of reported symptom measurements or patient status after 6 months or more. Data for certain groups remain insufficient, including children, adolescents, and those with complex co-occurring conditions.

The evidence highlights what is known—and what is still uncertain—about the use of Claben. Research provides context but not individual predictions, and the evidence quality varies across studies.

Frequently Asked Questions (FAQ)

Common questions about Claben (FAQ)

Q: How long will it take for the Claben patch to start relieving my pain?

A: Studies and official information indicate that the Claben patch is designed to provide targeted, local pain relief. In clinical trials, the reduction in pain associated with this topical system was reported to begin as early as 4 to 6 hours after application.

Q: What is the typical starting dose of Claben tablets?

A: For Claben tablets, which contain the active ingredient Glibenclamide, official dosing information provides guidance for starting the medicine. The usual recommended initial dose for Glibenclamide used alone is a small amount taken orally once daily. This dose is determined and then adjusted by a healthcare professional based on the individual patient's medical needs.

Q: Is it okay to crush or chew the Claben tablets?

A: Regulatory information and standard administration guidelines for Glibenclamide tablets typically advise that the tablets should be swallowed whole. Altering the tablet is generally not recommended unless a healthcare professional advises otherwise.

Q: What are the most common side effects of Claben?

A: According to the official product information for the topical patch, the most common side effects reported by adult patients in clinical trials included itching at the application site and nausea. For children using the patch, the most frequently reported adverse reactions were headache and itching at the application site.

Q: What is the difference between Claben and other sulfonylurea drugs?

A: Claben tablets contain Glibenclamide, which is categorized as a second-generation sulfonylurea. It is classified as a second-generation agent, which means it achieves its therapeutic effect at a higher potency than older sulfonylureas. This class of medications also includes other drugs like glipizide and glimepiride.

Q: Where should I throw away my used or expired Claben tablets?

A: Unused or expired Claben tablets must be disposed of properly using an official drug take-back program as the main method. If no take-back program is available, official guidance suggests mixing the medication with an undesirable substance before sealing it and placing it in the trash.

Q: Where should I throw away my used or expired Claben patch?

A: To ensure safe disposal, official patient information requires that used Claben patches be folded in half so the sticky sides stick together. They must then be immediately thrown away in a trash receptacle out of the sight and reach of children and pets.

Q: Can I get pregnant while taking Claben?

A: For the tablet form (Glibenclamide), official regulatory documents strongly advise against its use during pregnancy. For patients planning a pregnancy, healthcare professionals may recommend switching from Glibenclamide to insulin to help maintain blood glucose control.

How should Claben be stored and disposed of?

How to Store and Dispose of Claben?

Storing and disposing of Claben (Glibenclamide tablets) must follow official regulatory requirements to maintain product stability and ensure public safety.

Official Storage Requirements

Condition	Requirement
Environment	Store the tablets in a cool, dry, and dark place, protected from excess moisture and light.
Container	Keep the medication in the original container with the lid tightly closed to preserve its labeled stability, which is typically 36 months from the date of manufacture.
Safety	The medication must be kept out of the sight and reach of children.

Official Disposal Rules

To discard unused or expired Claben, patients should utilize an official drug take-back program. Disposing of the product must prevent its release into the environment, including avoiding sewage systems, water courses, or ground water, as specified in regulatory guidance.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Vietnam

A-Z Index:

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z